(Reuters) – China-based drug developer BeiGene said on Thursday the U.S. Food and Drug Administration (FDA) has delayed its decision on the company’s cancer drug as it was unable to conduct inspections in the country due to COVID-related travel curbs.
(This story refiles to correct day to Thursday from Friday in paragraph 1)
(Reporting by Leroy Leo in Bengaluru; Editing by Aditya Soni)
